PLEIADES: Daratumumab combinations for multiple myeloma

Treatment options for high risk relapsed/refractory multiple myeloma

Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory multiple myeloma

BCMA: A new biomarker for multiple myeloma

ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma

BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/refractory multiple myeloma

Practical considerations for introducing biosimilars

Successful implementation of biosimilars through effective communication

How real-world data generation can assist biosimilar implementation

Regulatory principles for biosimilar medicines

Biologics utilisation and its efficiency through a hospital pharmacy centralised management system

The science of biosimilarity: Immunogenicity